Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

French athlete handed six-month ban for doping
eventing
Livio and the French eventing team lost their slot in the Rio 2016 Olympic Games after the horse tested positive for a banned substance. (stock image)
Sanctions follow failed drugs test

French eventer Maxime Livio has been handed a fine and banned for six months after horse Qalao des Mers tested positive for a controlled medication substance.

A sample taken from the horse on 29 August last year tested positive for hydroxyethylpromazine sulfoxide, which is a metabolite of acepromazine.

After the findings were revealed last month, Livio and the French eventing team were disqualified from the FEI World Equestrian Games 2014. As a result, France lost its slot in the Rio 2016 Olympic Games.

As well as a six-month ban on Livio, which came into effect on 7 May, the FEI Tribunal ordered the athlete to pay CHF 2,500 in addition to covering the costs of the B sample analysis and contributing to the judicial procedure costs.

Acepromazine is a controlled medication substance on the FEI prohibited substances list. The list comprises substances that are regularly used to treat horses but are prohibited in competitions to maintain a level playing field.

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.